Trisotech
/wp-content/uploads/webinar2-Preauthorization-for-Targeted-Drug-thumb.jpg Webinars /webinars/ Preauthorization for Targeted Drug Therapy and Streamlining of the Appeals Targeted drug therapy can be very expensive, and insurance companies do not want to pay for it when it is not indicated. In the second webinar, we will discuss preauthorization for targeted drug therapy using Rituximab as an example. We will show how business models can streamline the appeals process for both the insurer and the provider. Analysis of the data can give insights that can result in process improvements.
Preauthorization for Targeted Drug Therapy and Streamlining of the Appeals
Resources

Webinars

Title Shadow

Automated Guidelines for Healthcare Reimbursement Series

Part 2: Preauthorization for Targeted Drug Therapy and Streamlining of the Appeals

As presented by:

John Svirbely, CMIO and Denis Gagné, CEO & CTO at Trisotech

Targeted drug therapy can be very expensive, and insurance companies do not want to pay for it when it is not indicated. In the second webinar, we will discuss preauthorization for targeted drug therapy using Rituximab as an example. We will show how business models can streamline the appeals process for both the insurer and the provider. Analysis of the data can give insights that can result in process improvements.

View Slides

Videos

Recorded webinars

View all videos
Attend a live webinar

    Learn how it works

    Request Demo

    Confirm your budget

    Request Pricing

    Discuss your project

    Request Meeting
    Graph

    If your Business runs on Rules, it should run on Trisotech!

    Get Digital Enterprise Suite